Irritable Bowel Syndrome With Diarrhea Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo Controlled Trial of Aldafermin (NGM282) for Treatment of Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
This single-center, randomized, double-blind, placebo-controlled study is designed to compare effects of aldafermin, (NGM282), 1 mg, and placebo given daily by subcutaneous injection on bowel functions and hepatic synthesis and fecal excretion of bile acids in patients with diarrhea associated with bile acid malabsorption (BAM).
This single-center, randomized, double-blind, placebo-controlled study is designed to compare effects of aldafermin, NGM282, 1 mg, and placebo given daily by subcutaneous injection on bowel functions and hepatic synthesis and fecal excretion of bile acids in patients with diarrhea associated with bile acid malabsorption (BAM). Thirty patients will receive either aldafermin (NGM282) or placebo, not both. The study includes a 7 to 28-day long prescreen period and a 28-day long treatment period for a maximum study duration of 56 days. Bowel pattern will be assessed by patient-recorded daily bowel pattern diaries. Serum 7-alpha C4 (C4) and fibroblast growth factor 19 (FGF-19) and fecal bile acids will be measured at baseline and Day 14 and Day 28 of treatment. Safety will be assessed through regular monitoring of adverse events, clinical laboratory results, 12-lead ECGs, physical examinations, and vital signs. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00552565 -
Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
|
Phase 3 | |
Completed |
NCT04950296 -
To Study the Efficacy and Safety of L. Plantarum UALp-05TM in Diarrhea- Predominant-irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02959983 -
Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use
|
Phase 4 | |
Withdrawn |
NCT02320318 -
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
|
Phase 3 | |
Completed |
NCT01303224 -
Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
|
Phase 2 | |
Recruiting |
NCT05646186 -
Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT03806959 -
Interest of Pan-capsule in Symptomatic Patients Suspected of Irritable Bowel Syndrome Requiring Colonoscopy
|
N/A | |
Completed |
NCT04129619 -
A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
|
Phase 2 | |
Recruiting |
NCT04855799 -
GI Permeability Change in Response to Aquamin®
|
Phase 2 | |
Completed |
NCT04662957 -
Multi Strain Probiotic Preparation in Patients With Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT04557215 -
Efficacy and Safety of Rifaximin With NAC in IBS-D
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05311293 -
Study on the Molecular Mechanism of Diarrhea-predominant Irritable Bowel Syndrome With Anxiety and Depression Based on Multi-omics Correlation Analysis
|
||
Completed |
NCT05277428 -
Clinical Study to Evaluate the IBS Symptoms Improving Effect and Safety of GTB1
|
N/A | |
Not yet recruiting |
NCT03221790 -
Effect of FODMAPs on Mucosal Inflammation in IBS Patients
|
N/A | |
Completed |
NCT03557788 -
Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome
|
Phase 4 | |
Completed |
NCT02757105 -
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
|
Phase 2 | |
Enrolling by invitation |
NCT06432569 -
Evaluation of Butyrate and Palmitoylethanolamide in IBS Patients (B/P3_1)
|
N/A | |
Recruiting |
NCT04830410 -
The Effects of Carbohydrates in Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03245645 -
FODMAP Reintroduction in Irritable Bowel Syndrome
|
N/A | |
Terminated |
NCT02120027 -
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
|
Phase 3 |